Lenalidomide Biocon (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone marrow.

• Multiple Myeloma: reduces disease progression and improves survival when used in combination regimens.
• Myelodysplastic Syndromes: decreases transfusion dependence and modifies disease course in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to tumor control as part of salvage therapy in relapsed or refractory cases.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in anti‑angiogenic effects, modulation of cytokine production, and enhanced immune‑mediated tumor cell killing. The downstream effects include reduced proliferation of malignant plasma cells and restoration of normal immune surveillance, while also decreasing vascular endothelial growth factor levels in the tumor microenvironment.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness or lack of energy.
• Diarrhea: loose stools, often mild to moderate.
• Nausea: feeling of sickness, may be accompanied by vomiting.
• Rash: skin redness or mild eruption.
• Low blood counts: decreased neutrophils, platelets, or red cells.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly low neutrophil count increasing infection risk.
• Severe thrombocytopenia: very low platelet count leading to bleeding.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: significant liver enzyme elevation or liver injury.

When prescribing lenalidomide, clinicians should consider several safety and handling precautions.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess thrombotic risk: evaluate history of clotting disorders and consider prophylaxis.
• Evaluate renal function: adjust use in patients with impaired kidney function.
• Avoid pregnancy: ensure effective contraception for both male and female patients of reproductive potential.
• Review drug interactions: check concomitant medications that may increase toxicity.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.
• P-glycoprotein inhibitors: potential increase in plasma levels.
• Live vaccines: risk of infection due to immunomodulation.
• NSAIDs: may exacerbate gastrointestinal irritation.